Healing & recovery
Restore your intestinal barrier and protect against gluten damage.
Start here
Larazotide is a small peptide taken by mouth, developed for celiac disease. It tightens the junctions between intestinal cells so gluten fragments cannot leak through the gut wall and trigger the immune system. It has been through late-stage human trials with a good safety record, but it is not FDA-approved.
Larazotide is a peptide designed to tighten the intestinal barrier in celiac disease. It binds to proteins that hold intestinal cells together, preventing harmful gluten from leaking through and triggering immune reactions.
Larazotide (AT-1001) is an 8-amino-acid peptide (octapeptide) 7 that adjusts tight junction proteins (the proteins that seal gaps between gut cells), specifically claudins and ZO-1. This stops dietary antigens (food particles that trigger the immune system) from slipping between gut cells in celiac disease (paracellular transport).
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 7 sources at the bottom.
Gut Barrier Protection
Larazotide is specifically designed to strengthen and protect the intestinal barrier by blocking zonulin, the protein that opens tight junctions. This prevents undigested food particles and harmful substances from passing through intestinal walls.
Celiac Disease Management
Clinical trials show larazotide significantly reduces gastrointestinal symptoms in celiac patients during gluten challenge, including reduced diarrhea, abdominal pain, and inflammation markers.
Safety & Tolerability
Extensive clinical testing demonstrates excellent safety with few adverse events. It's well-tolerated across different populations and has a favorable side effect profile compared to many other therapeutic options.
The most-asked question
The research-reported range is 0.5 mg, once daily.
Celiac symptom control, Intestinal barrier support
0.5 mg
Trial-established dose: in a Phase 2b randomized controlled trial in celiac disease, 0.5 mg three times daily met the primary endpoint with fewer symptoms vs placebo. Notably, the higher 1 mg and 2 mg doses showed no benefit over placebo, so 0.5 mg is the effective dose 6. Taken before meals as a local intestinal tight-junction regulator 1.
The ceiling: 1000 mcg (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Larazotide:
Larazotide comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use Larazotide exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Larazotide's recorded schedule.
Timing
Take Larazotide at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
Larazotide can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
Larazotide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Some patients experience mild nausea, particularly when taking the peptide on an empty stomach. This is typically mild and temporary.
What to do Take larazotide with food or a light meal to minimize nausea. Try ginger tea or small frequent meals throughout the day.
Occasional mild cramping or discomfort reported during the adjustment period. Usually diminishes after the first week of treatment.
What to do Use a heating pad, practice gentle stretching, and ensure adequate hydration. Contact your doctor if cramping is severe or persistent.
Rare reports of mild fatigue, possibly related to the body's healing response. Energy levels typically normalize quickly.
What to do Ensure adequate sleep, maintain good nutrition, and stay physically active. Supplement with B vitamins if deficient.
Worth knowing about, but most people never see these.
Some patients report temporary loose stools during initial treatment. This paradoxically improves with continued use as the barrier heals.
What to do Ensure adequate hydration and electrolyte intake. Consider dietary adjustments to increase fiber gradually. Usually resolves within 1-2 weeks.
Rare, but if any of these happen, stop and contact a medical professional.
Very rare hypersensitivity reactions to the peptide or inactive ingredients. Signs include rash, itching, swelling, or difficulty breathing.
What to do Seek immediate medical attention if any signs of allergic reaction develop. Discontinue use and inform healthcare provider immediately.
Week by week
Is it right for you?
Larazotide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Can make the gut leakier and may work against larazotide's gut-barrier protection
Alcohol damages the seals between gut cells and can undermine larazotide's benefits
May upset the helpful gut bacteria needed for the barrier to heal
Works together to repair the gut barrier: glutamine feeds the cells that line the gut while larazotide controls the seals between gut cells (tight junctions)
Supports a healthy gut microbiome (the community of gut bacteria) while larazotide restores the gut barrier, so probiotics settle in better
Needed to build the proteins that seal gut cells together and to repair the cells that line the gut
Generally safe to take alongside Larazotide. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Larazotide is particularly well-suited for individuals focused on managing celiac disease symptoms despite strict gluten avoidance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 6.
Larazotide is particularly well-suited for individuals focused on reducing accidental gluten exposure damage. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Larazotide is particularly well-suited for individuals focused on restoring digestive comfort and nutrient absorption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Larazotide is particularly well-suited for individuals focused on supporting intestinal healing and barrier function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Larazotide (AT-1001) is a synthetic tight-junction regulator. In Phase 2 celiac disease trials it reduced symptoms at the 0.5 mg dose, but a pooled analysis found no improvement in intestinal permeability versus placebo; safety was comparable to placebo 16. The mechanism—zonula occludens-1 modulation—is specific to epithelial (surface-lining tissue) tight junctions without broad immunosuppression. Gastrointestinal side effects (nausea, diarrhea, abdominal pain) occur in 10-20% of patients but are typically mild and resolve with dose adjustment or continued exposure. FDA feedback on Phase 3 trials indicated efficacy trends but required additional manufacturing and clinical data before approval consideration.
Larazotide safety derives from Phase 2 randomized controlled trials, including a 342-patient trial in Gastroenterology 6 and a pooled analysis of four trials with 626 patients 1, with tolerability comparable to placebo. Serum enzyme elevation was minimal and reversible. Phase 3 trial data remain unpublished as of 2025, but regulatory interactions with FDA suggest development is ongoing. The peptide demonstrates selective intestinal barrier modulation without systemic (affecting the whole body) toxicity in evaluated cohorts.
Keeping it good
Store Larazotide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Larazotide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2022
Meta-analysis (a combined analysis) of four randomized trials showed larazotide clearly improved gastrointestinal (stomach and gut) symptoms when patients were exposed to gluten. The peptide kept a favorable safety profile with few adverse events (unwanted effects), supporting its potential as an add-on therapy.
Hoilat GJ, et al.
2026
Larazotide acetate acts as a zonulin antagonist (it blocks zonulin, a protein that opens the seals between gut cells) to restore the gut barrier in celiac disease. The review highlighted larazotide and other barrier-restoring therapies as important complements to avoiding gluten.
Damianos JA, et al.
2024
In acute pancreatitis models (lab models of sudden pancreas inflammation), larazotide lowered intestinal damage scores and cut the frequency of bacterial translocation (gut bacteria crossing into the body) from 100% to 50%. Its effect on tight junctions (the seals between gut cells) stopped harmful bacteria from crossing the gut barrier.
Karahan D, et al.
2024
Larazotide is a new drug option for celiac disease patients who still have symptoms. The peptide may improve quality of life beyond what a traditional gluten-free diet gives.
D'heedene MD, et al.
2021
Larazotide emerged as a leading tight junction regulator (a drug that controls the seals between gut cells) with strong clinical trial data. Its way of working, blocking zonulin receptors (docking sites for zonulin), is a new approach, different from traditional gluten-degrading enzymes (enzymes that break down gluten).
Kulkarni A, et al.
2015
In 342 adults with celiac disease on a gluten-free diet, larazotide acetate 0.5 mg three times daily met the primary endpoint (the main goal of the trial) with fewer symptoms than placebo. The 1 mg and 2 mg doses showed no benefit over placebo.
Leffler DA, Kelly CP, Green PHR, et al.
2022
In mice, gut permeability (gut leakiness) caused by lupus-derived R. gnavus strains (gut bacteria from people with lupus) was fully reversed by larazotide acetate taken by mouth. The authors describe it as an octapeptide (an 8-amino-acid chain) and a specific molecular antagonist of zonulin (a blocker of zonulin).
Silverman GJ, Deng J, Azzouz DF
If this isn't the right fit
Your questions
No, larazotide is not a cure for celiac disease. It's a therapeutic treatment that helps manage symptoms and protect the intestinal barrier. The gold standard treatment remains a strict gluten-free diet. However, larazotide may provide additional protection, especially for those exposed to small amounts of gluten accidentally or those struggling with persistent symptoms despite dietary compliance.
No, you should not intentionally consume gluten even while taking larazotide. The medication provides additional barrier protection, but it's not designed to allow normal gluten consumption. In clinical trials, larazotide was used during controlled gluten challenges under medical supervision. Continue following a strict gluten-free diet as the foundation of celiac disease management.
Larazotide is unique because it targets the fundamental mechanism of intestinal barrier dysfunction through zonulin antagonism. Rather than suppressing the immune system like some treatments, it restores normal intestinal barrier function. This mechanism-based approach offers potential advantages in safety and effectiveness for barrier restoration.
Larazotide is currently in Phase 3 clinical trials, which are the final stage before FDA review. If trials are successful and the FDA approves it, it could become available within the next few years. However, timelines for drug approval can vary. Check ClinicalTrials.gov for the most current trial status and estimated completion dates.
Larazotide should not be used by people with known hypersensitivity to the peptide, severe gastrointestinal obstruction, or compromised kidney function. Pregnant and breastfeeding women should avoid it due to limited safety data. Always consult with a gastroenterologist before starting treatment to ensure it's appropriate for your specific situation.
Research is still ongoing regarding larazotide's effectiveness in non-celiac gluten sensitivity and other conditions involving intestinal permeability. While clinical trials have focused on celiac disease, the mechanism of action suggests potential benefits for other conditions characterized by compromised barrier function. Discuss with your healthcare provider about potential off-label uses.
A gluten-free diet is the foundation of celiac disease management and must continue. Larazotide is designed to work alongside this diet. While a gluten-free diet prevents new gluten from damaging the barrier, larazotide actively helps restore and protect an already-damaged barrier. Together, they offer comprehensive barrier protection and symptom management.
7 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Larazotide research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Talk to a clinician before taking anything.
PeptideGeek